Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,408 Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)
Depression/Depressed State
Primary: Number of Participants With Adverse Drug Reactions — 312; 4 Participants
N/A N=341 Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
HIV
Primary: Number of Participants Who Reported Primary Male Partner Completed HIV Testing at a Healthcare Facility — 3; 15; 3; 33 Participants
Phase 4 N=261 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Breast Cancer
Primary: Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia. — 25 Participants
Phase 3 N=129 Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Acquired Immune Deficiency Syndrome (AIDS) · HIV Infections
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) — 23840.1 hr*ng/mL
Phase 2 N=336 Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Dry Eye Disease (DED)
Primary: Corneal Fluorescein Staining (CFS) Total (National Eye Institute (NEI) Grading) — -1.78; -2.11; -0.93 score on a scale
Phase 4 N=109 Response to Anti-hypertensives in Pregnant and Postpartum Patients
Hypertension in Pregnancy · Preeclampsia
Primary: Time to Achieve Non Severe Range Blood Pressure — 10; 20 minutes
Phase 1 N=32 Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alvocidib — 30; 60 mg/m2
N/A N=280 Ultrasonography Versus Palpation for Spinal Anesthesia in Obese Parturients Undergoing Cesarean Delivery
Anesthesia, Spinal · Cesarean Section · Spinal Ultrasound
Primary: Number of Needle Passes Required to Obtain Free Cerebrospinal Fluid Flow — 3; 3 needle passes — p=0.62
Phase 2 N=30 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Phase 1 N=9 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
Healthy Volunteers
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 6; 0; 0 Participants
N/A N=100 Perioperative Blood Pressure Screening to Improve Long-term Cardiovascular Health
Blood Pressure
Primary: Patients Reporting Primary Care Follow-up — 36; 36 Participants
N/A N=27 A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.
Alveolar Ridge Preservation · Tooth Extraction
Primary: Quality of the Newly Formed Bone — 24.14; 19.12 Percentage of newly formed bone
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
N/A N=56 A Post-Market Study Evaluating the Prodigy MRI and Proclaim Elite MR Conditional SCS Systems
Chronic Pain
Primary: The Rate of the MRI Scan-related Adverse Events — 0 participants